# Antiviral Activity of Oral Probiotics

> **NCT05374070** · NA · UNKNOWN · sponsor: **John Hale** · enrollment: 20 (estimated)

## Conditions studied

- Lower Respiratory Tract Infection
- Upper Respiratory Tract Infection

## Interventions

- **DIETARY_SUPPLEMENT:** Streptococcus salivarius K12 Powder 1 Billion colony forming units /g)
- **DIETARY_SUPPLEMENT:** Streptococcus salivarius K12 Powder (1 Billion colony forming units /g) with a prebiotic included
- **DIETARY_SUPPLEMENT:** Streptococcus salivarius M18 Powder (1 Billion colony forming units /g)
- **DIETARY_SUPPLEMENT:** Streptococcus salivarius M18 Powder (1 Billion colony forming units /g) with a prebiotic included

## Key facts

- **NCT ID:** NCT05374070
- **Lead sponsor:** John Hale
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-23
- **Primary completion:** 2022-06-23
- **Final completion:** 2022-08-15
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05374070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05374070, "Antiviral Activity of Oral Probiotics". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05374070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*